Target identification and validation using AI for literature-based insights: Causaly & Pierre Fabre
Causaly and Pierre Fabre co-hosted a joint webinar on the 28th of October, addressing how pharmaceutical companies, in the context of Translational Medicine, combine Natural Language Processing and other AI technologies with expert judgement to investigate and select promising therapeutic targets.
0 min read
Written by
Yiannis Kiachopoulos
- Categories
- Target Selection
Receive the latest newsletter directly to your inbox
Causaly and Pierre Fabre joint webinar
Causaly and Pierre Fabre co-hosted a joint webinar on the 28th of October, addressing how pharmaceutical companies, in the context of Translational Medicine, combine Natural Language Processing and other AI technologies with expert judgement to investigate and select promising therapeutic targets.
Request access for this webinar to learn more about how:
- Pierre Fabre approaches the data challenges that come with target identification and validation, and how AI contributes effectively to better outcomes.
- Causaly’s AI platform supports researchers to understand critical relationships between targets, drugs and indications that are continuously mined from millions of research publications and merged into a high-precision Causal Knowledge Graph.
Causaly AI was proven to save 80% of their research time.
Want to know more about this session? Please request access to the recording here.
More on Target Selection